Lucid Diagnostics, a New York-based maker of diagnostic tests for esophageal precancer and cancer, filed for a $58 million IPO, per Axios. The pre-revenue company plans to list on the Nasdaq.
Lucid Files for $58M IPO
Related Posts
Intrepid USA Planning for Major Growth Push with New PE Partners
Intrepid expects to complete recapitalization toward the end of this year or in early 2022.
Rosy Wellness Raises $1.2M to Grow Women’s Sexual Health Platform
Combined with previous seed rounds led by Austin-based True Wealth Ventures, Rosy has raised $4.2 million to date. The startup currently has 6 full-time employees and about 20 contractors.
Oma Fertility Raises $37.5M in Equity and Debt
The seed and Series A rounds were led by JAZZ Venture Partners, Root Ventures, Mithril Capital, Global Asset Capital and Free Solo Ventures.
Stella Raises $7M for PTSD Treatment
The funds were raised from Sterling Partners.